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Background: Chronic bronchitis (CB) is one of the classic phenotypes of COPD. The aims of our study were to
investigate genetic variants associated with COPD subjects with CB relative to smokers with normal spirometry,
and to assess for genetic differences between subjects with CB and without CB within the COPD population.
Methods: We analyzed data from current and former smokers from three cohorts: the COPDGene Study; GenKOLS
(Bergen, Norway); and the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE).
CB was defined as having a cough productive of phlegm on most days for at least 3 consecutive months per year
for at least 2 consecutive years. CB COPD cases were defined as having both CB and at least moderate COPD based
on spirometry. Our primary analysis used smokers with normal spirometry as controls; secondary analysis was
performed using COPD subjects without CB as controls. Genotyping was performed on Illumina platforms; results
were summarized using fixed-effect meta-analysis.
Results: For CB COPD relative to smoking controls, we identified a new genome-wide significant locus on chromosome
11p15.5 (rs34391416, OR = 1.93, P = 4.99 × 10-8) as well as significant associations of known COPD SNPs within FAM13A. In
addition, a GWAS of CB relative to those without CB within COPD subjects showed suggestive evidence for association
on 1q23.3 (rs114931935, OR = 1.88, P = 4.99 × 10-7).
Conclusions: We found genome-wide significant associations with CB COPD on 4q22.1 (FAM13A) and 11p15.5 (EFCAB4A,
CHID1 and AP2A2), and a locus associated with CB within COPD subjects on 1q23.3 (RPL31P11 and ATF6). This study
provides further evidence that genetic variants may contribute to phenotypic heterogeneity of COPD.
Trial registration: ClinicalTrials.gov NCT00608764, NCT00292552
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COPD, a leading cause of morbidity and mortality, is
characterized by persistent airflow limitation and pheno-
typic heterogeneity. While cigarette smoking is a major
risk factor for COPD, the response to cigarette smoke is
highly variable [1]. Chronic bronchitis (CB) and emphy-
sema represent two classic phenotypes of COPD [2]. How-
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unless otherwise stated.phlegm, can occur in the absence of COPD [3]. Some
studies have suggested that CB and emphysema have dif-
ferent genetic determinants [4,5]. CB has been reported to
be associated with frequent respiratory exacerbations, in-
creased respiratory symptoms, poor quality of life, and
even increased mortality [6-8].
Although candidate gene testing and linkage analysis
have been used to search for CB-related genetic determi-
nants in selected populations [9,10] and recently a
genome-wide association meta-analysis has reported
genetic variants associated with chronic mucus hyperse-
cretion mainly in subjects from the general population
[11], genome-wide association studies (GWAS) of CB
within COPD subjects have not been reported. Our. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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associated with COPD-related CB. We also hypothesized
that genetic heterogeneity exists according to the pres-
ence or absence of CB within COPD subjects. We ad-
dressed these hypotheses by comparing COPD subjects
with CB to smokers with normal spirometry and to
COPD subjects without CB as control groups.Methods
Study cohorts
Subjects were current and former smokers from three
studies: the non-Hispanic whites (NHWs) from the
COPDGene Study (NCT00608764 at, https://clinicaltrials.
gov); GenKOLS (Bergen, Norway); and the Evaluation of
COPD Longitudinally to Identify Predictive Surrogate End-
points (ECLIPSE, NCT00292552 at, https://clinicaltrials.
gov). All subjects had self-described European white ances-
try. The design and procedures for each participating study
have been previously described [12-14]. For supplementary
analysis, the African Americans (AAs) of the COPDGene
Study were included. Institutional review board approval
was obtained at each participating clinical center; all
subjects provided written informed consent. This study
was approved by the Partners HealthCare Institutional
Review Board (COPDGene, 2007P000554; GenKOLS,
2009P000790; ECLIPSE, 2005P002467).Figure 1 Genome-wide association study design for chronic bronchit
obstructive pulmonary disease; GOLD = Global initiative for chronic Obs
post-bronchodilator FEV1/FVC < 0.7 and FEV1 < 80% predicted. Normal s
0.7 and FEV1 ≥ 80% predicted.Variable definitions
CB was defined as chronic productive cough for 3 months
in each of 2 successive years [15]. CB COPD cases were
defined as having both CB and COPD of at least spirom-
etry grade 2 (post-bronchodilator FEV1/FVC <0.7 and
FEV1 < 80% predicted), defined by the Global initiative for
chronic Obstructive Lung Disease (GOLD 2-4) [16]. For
CB COPD cases, primary analysis used current or former
smokers with normal spirometry (post-bronchodilator
FEV1/FVC ≥0.7 and FEV1 ≥ 80% predicted) as a control
group. A secondary analysis was performed using COPD
subjects without CB as controls to explore genetic hetero-
geneity within COPD subjects. Additionally, we performed
GWAS of COPD subjects without CB relative to smoking
controls for comparison to our results in COPD CB sub-
jects (Figure 1). Additional variable definitions for comple-
mentary analyses are available in an online supplement.
Genotyping quality control and imputation
Genotyping was performed using Illumina platforms
[HumanOmniExpress for the COPDGene cohort, the
HumanHap 550 (V1, V3, and Duo) for the GenKOLS
cohort, and HumanHap 550V3for the ECLIPSE cohort;
Illumina, Inc., San Diego, CA]. Genotype imputation on
the COPDGene cohorts was performed using MaCH
[17] and minimac [18] using 1000 Genomes [19] Phase I
v3 European (EUR) reference panels or cosmopolitanis. Definition of abbreviations: CB = chronic bronchitis; COPD= chronic
tructive Lung Disease. GOLD 2-4 was defined as having a
pirometry was defined as having a post-bronchodilator FEV1/FVC ≥
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tails on genotyping quality control and imputation for
the GenKOLS and ECLIPSE cohorts have been previ-
ously described [5,14,20-23]. If variants passed genotyp-
ing or imputation quality control in all three cohorts,
they were included for analysis.
Statistical analysis
Logistic regression analysis of SNPs under an additive
model of inheritance with case-control status as the out-
come was performed in each cohort with adjustment for
age, gender, pack-years of cigarette smoking and genetic
ancestry-based principal components using PLINK 1.07
[24], as previously described [21-23]. Imputed genotypes
were analyzed in a similar manner, using SNP dosage
data in PLINK 1.07 [24]. We performed fixed-effects
meta-analysis [25] using METAL (version 2011-3-25)
[26] and R 2.15.1 (www.r-project.org) with the meta-
package. Heterogeneity was assessed by calculating both
I2 [27] and P values for Cochran’s Q. In genomic regions
with evidence of genetic heterogeneity, we also used a
modified random-effects model optimized to detect asso-
ciations under heterogeneity since the fixed effects model
is based on inverse-variance-weighted effect size [28].
Genomic inflation factors [29] were calculated using
GenABEL [30]. We used LocusZoom [31] to generate
regional association plots, using the 1000 Genomes EUR
reference data to calculate linkage disequilibrium (LD).
We used permutation testing [23] to assess differences
in ORs of previous known genome-wide significant
SNPs between two meta-analyses.
Results
GWAS of CB COPD relative to smokers with normal
spirometry
Baseline characteristics of each of the three primary
cohorts are summarized in Table 1.
For the primary analysis of CB COPD relative to
smokers with normal spirometry, the combined GWAS
of three cohorts included 1,662 CB COPD cases andTable 1 Baseline characteristics of COPD subjects with chroni
control group
COPDGene NHWs GenK
COPD with CB Controls COPD
n 844 2,534 311
Age, years 62.8 (8.3) 59.5 (8.7) 65.3 (
Pack-years 59.2 (28.6) 37.8 (20.3) 33.9 (
Current smoker (%) 53.3 39.6 54.0
FEV1,% predicted 48.6 (17.4) 96.8 (11.0) 46.9 (
Sex (% male) 61.8 49.3 64.6
Data are presented as mean (SD) or percentage, as appropriate.
Definition of abbreviations: CB chronic bronchitis, NHW non-Hispanic white.3,520 controls. The quantile-quantile (Q-Q) plot showed
no evidence of significant residual population stratifica-
tion (Figure 2A; lambda = 1.03). Figure 3A shows a
genome-wide significant association within the previ-
ously reported COPD susceptibility genome-wide signifi-
cant region on chromosome 4q22.1 in FAM13A and a
second genome-wide significant association in a novel
region on 11p15.5. The results for the most significant
SNPs at each of these loci are listed in Table 2. Figure 4
displays the regional association plots for these two re-
gions. The top 12 SNPs in the meta-analysis were lo-
cated on 4q22.1 (FAM13A) and either identical to, or in
strong LD (r2 ≥ 0.97) with, the top SNPs previously de-
scribed in GWASs of pulmonary function [32,33] and
COPD [21-23].
The novel locus on 11p15.5 encompasses a region
where three genes are annotated: EF-hand calcium bind-
ing domain 4A (EFCAB4A), chitinase domain containing
1 (CHID1), and adaptor-related protein complex 2, alpha
2 subunit (AP2A2). The most significant SNP at this
locus was rs34391416 (EFCAB4A), with a P value of
4.99 × 10-8. There was some evidence of heterogeneity
(P = 0.01 for Cochran’s Q, I2 = 79). However, a meta-
analysis using a modified random effects model showed
more highly significant P values: P = 1.66 × 10-8 at
rs34391416 (EFCAB4A), P = 7.56 × 10-9 at rs147862429
(CHID1), and P = 1.11 × 10-8 at rs143705409 (AP2A2).
GWAS of CB COPD relative to COPD subjects without CB
A GWAS of CB within COPD subjects from three stud-
ies included the same number of COPD CB cases and
3,777 COPD subjects without CB as a control group.
Table 3 showed baseline characteristics of COPD sub-
jects, and there is a corresponding Q-Q plot in Figure 2B
(lambda = 1.01). We found a novel suggestive locus on
1q23.3, which did not reach genome-wide significant
levels (rs114931935, P = 4.99 × 10-7, Table 4 and Figure 3B).
This locus includes ribosomal protein L31 pseudogene 11
(RPL31P11) and activating transcription factor 6 (ATF6)
(Figure 5).c bronchitis and smokers with normal spirometry as a
OLS ECLIPSE
with CB Controls COPD with CB Controls
808 507 178
10.0) 55.6 (9.7) 62.3 (7.7) 57.5 (9.4)
20.2) 19.7 (13.6) 51.6 (30.2) 32.1 (24.8)
41.2 51.4 40.1
16.8) 94.9 (9.2) 46.3 (15.3) 107.9 (13.7)
50.1 75.7 57.9
Figure 2 The quantile–quantile plots for the three-cohort meta-analysis including 1000 Genomes project imputed data for (A) COPD
subjects with chronic bronchitis (CB) versus smoking controls and (B) CB versus no CB within COPD subjects, after adjustment for age,
sex, pack-years of cigarette smoking and genetic ancestry using principal components.
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CB versus COPD without CB identified a genome-wide
significant SNP, rs12692398 on 2p25.1, we performed a
meta-analysis of two studies (COPDGene NHWs and
GenKOLS), which also demonstrated the same SNP as a
genome-wide significant SNP (Additional file 1: Table S1
and Additional file 1: Figure S1). It is located within
cystin-1 (CYS1), encoding a cilia-associated protein. ThisFigure 3 Manhattan plots of –log10 P values for meta-analysis of thre
versus smoking controls and (B) CB versus no CB within COPD subject
and genetic ancestry using principal components.SNP did not demonstrate evidence for association to CB
within ECLIPSE COPD cases.
Complementary analyses
To explore whether our results were similar when in-
cluding an additional racial group, a supplemental meta-
analysis of four cohorts by adding AAs of COPDGene
was performed for CB COPD relative to smokinge cohorts for (A) COPD subjects with chronic bronchitis (CB)
s, after adjustment for age, sex, pack-years of cigarette smoking
Table 2 Top results of the meta-analysis for COPD subjects with chronic bronchitis versus smokers with normal spirometry in COPDGene non-Hispanic white,





FRQ COPDGene NHWs GenKOLS ECLIPSE Overall
OR (95% CI) P OR (95% CI) P OR (95 CI) P OR (95% CI) P I2 Q
4q22 FAM13A rs2869967 C 0.41 1.33 (1.17-1.51) 9.92 × 10-6 1.56 (1.25-1.95) 8.08 × 10-5 1.40 (1.04-1.88) 2.66x10-2 1.38 (1.25-1.53) 5.61 × 10-10 0 0.46
4q22 FAM13A rs2045517 T 0.40 1.33† (1.17-1.51) 9.87 × 10-6 1.56† (1.25-1.95) 7.88 × 10-5 1.40† (1.04-1.88) 2.67 × 10-2 1.38 (1.25-1.53) 5.63 × 10-10 0 0.46
4q22 FAM13A rs7671167 T 0.51 1.32 (1.16-1.49) 1.69 × 10-5 1.44 (1.15-1.80) 1.27 × 10-3 1.41 (1.06-1.87) 1.73 × 10-2 1.35 (1.22-1.50) 5.58 × 10-9 0 0.75
4q22 FAM13A rs2904259 C 0.50 1.31† (1.16-1.49) 1.85 × 10-5 1.44† (1.15-1.80) 1.33 × 10-3 1.41† (1.06-1.87) 1.73 × 10-2 1.35 (1.22-1.49) 6.25 × 10-9 0 0.75
11p15 EFCAB4A rs34391416 A 0.05 2.38 (1.81-3.13) 6.11 × 10-10 1.21† (0.68-2.16) 5.18 × 10-1 0.80† (0.35-1.79) 5.79 × 10-1 1.93 (1.53-2.45) 4.99 × 10-8 79 0.01
11p15 CHID1 rs147862429 T 0.05 2.77† (2.02-3.81) 2.90 × 10-10 1.34† (0.71-2.53) 3.68 × 10-1 0.58† (0.24-1.39) 2.23 × 10-1 2.09 (1.60-2.74) 7.87 × 10-8 85 0.001
2q14 PCDP1 rs139257032 T 0.02 2.78† (1.57-4.92) 4.60 × 10-4 4.17† (1.82-9.57) 7.41 × 10-4 10.79† (1.27-91.39 2.91 × 10-2 3.35 (2.12-5.30) 2.53 × 10-7 0 0.4
15q26 MCTP2 rs12910412 G 0.46 1.29† (1.14-1.46) 4.37 × 10-5 1.30† (1.03-1.64) 2.49 × 10-2 1.33† (0.98-1.78) 6.37 × 10-2 1.30 (1.17-1.44) 5.22 × 10-7 0 0.99
11p15 CHID1 rs139090846 T 0.01 4.65† (2.77-7.80) 5.67 × 10-9 1.13† (0.33-3.89) 8.41 × 10-1 0.75† (0.19-2.91) 6.78 × 10-1 3.15 (2.01-4.94) 5.62 × 10-7 78 0.01
11p15 AP2A2 rs143705409 G 0.05 2.62† (1.93-3.56) 7.19 × 10-10 1.32† (0.73-2.40) 3.61 × 10-1 0.52† (0.24-1.11) 8.95 × 10-2 1.92 (1.49-2.49) 6.16 × 10-7 88 0.0002
11p15 AP2A2 rs185786041 C 0.05 2.61† (1.92-3.54) 8.44 × 10-10 1.31† (0.73-2.35) 4.26 × 10-1 0.54† (0.26-1.11) 9.50 × 10-2 1.89 (1.47-2.44) 9.20 × 10-7 88 0.0002
11p15 AP2A2 rs117455145 G 0.05 2.61† (1.92-3.54) 8.50 × 10-10 1.31† (0.73-2.34) 4.27 × 10-1 0.54† (0.26-1.11) 9.28 × 10-2 1.89 (1.46-2.43) 9.68 × 10-7 88 0.0002
Definition of abbreviations: CI confidence interval, FRQ risk allele frequency, NHW non-Hispanic white, OR odds ratio, SNP single nucleotide polymorphism.














Figure 4 Local association plots for significant loci in the meta-analysis of cases with chronic bronchitis and COPD versus smoking
control subjects in COPDGene non-Hispanic whites, GenKOLS, and ECLIPSE. A. rs2869967 on chromosome 4q22.1. B. rs34391416 on 11p15.
The x-axis is chromosomal position, and the y-axis shows the –log10 P value. The most significant SNP at each locus is labeled in purple, with
other SNPs colored by degree of linkage disequilibrium (r2). Plots were created using LocusZoom.
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characteristics of AAs of COPDGene. The meta-analysis
including 1,844 cases and 5,269 controls revealed similar
results to those of three cohorts, with the exception of
SNPs in both CHID and AP2A2, which were excluded
because of their rarity in AA subjects (minor allele
frequency < 0.01). The novel top SNP, rs34391416
(EFCAB4A), was genome-wide significant (OR = 1.93,
P = 2.66 × 10-8).
Since CB was present in some of our smoking con-
trols, a GWAS of CB COPD versus smoking controls
without CB (n = 3,101) was performed for each of our
three cohorts and then meta-analyzed. These results
were similar, although the novel top SNP on 11p15.5 was
slightly reduced in statistical significance (rs34391416,
OR = 1.98, P = 6.50 × 10-8). However, a meta-analysis of
four cohorts including AAs of COPDGene (n = 4,628)
showed genome-wide significance of the same SNP (OR =
1.98, P = 2.76 × 10-8). Baseline characteristics of smoking
controls without CB were summarized in Additional file 1:
Table S3.Table 3 Baseline characteristics of COPD subjects with chroni
COPDGene NHWs Ge
CB No CB CB
N 844 1968 31
Age, years 62.8 (8.3) 65.5 (8.0) 65
Pack-years 59.2 (28.6) 55.1 (27.6) 34
Current smoker (%) 53.3 26.7 54
FEV1,% predicted 48.6 (17.4) 50.1 (18.2) 46
Sex (% male) 61.8 53.0 64
Data are presented as mean (SD) or percentage, as appropriate.
Definition of abbreviations: CB chronic bronchitis, NHW Non-Hispanic white.Because COPD subjects with CB were more likely to
be current smokers, complementary meta-analyses were
performed with adjustment for current smoking status
as well as age, gender, pack-years of cigarette smoking
and genetic ancestry-based principal components. In meta-
analyses using smokers with normal spirometry as a control
group, FAM13A SNPs remained genome-wide significant.
One of the previously reported COPD risk loci, 15q25, was
nearly genome-wide significant (P = 6.58 × 10-8). However,
the novel SNP on 11p15 (rs34391416) was not genome-
wide significant (P = 5.25 × 10-7 in three Caucasian co-
horts and P = 2.60 × 10-7 in four cohorts including
AAs, Additional file 1: Table S4). On the other hand, a
meta-analysis using COPD subjects without CB as a
control group, with adjustment for current smoking
status, provided lower (but not genome-wide signifi-
cant) P values of top SNPs from the secondary analysis
of COPD with CB vs. COPD without CB (Additional
file 1: Table S5).
We assessed the top SNPs of CB COPD susceptibility
relative to smokers with normal spirometry (the primaryc bronchitis (CB) and those without CB within each cohort
nKOLS ECLIPSE
No CB CB No CB
1 552 507 1257
.3 (10.0) 65.7 (10.1) 62.3 (7.7) 64.2 (6.8)
.0 (20.4) 30.9 (17.3) 51.6 (30.2) 49.8 (26.2)
.0 42.8 51.4 28.5
.9 (16.8) 52.7 (17.5) 46.3 (15.3) 48.2 (15.7)
.6 57.6 75.7 63.5
Table 4 Top results of the meta-analysis for chronic bronchitis (CB) versus no CB within COPD subjects of COPDGene















1q23 RPL31P11 rs114931935 A 0.04 1.98†
(1.42-2.78)
6.43 × 10-5 2.11†
(1.07-4.15)
3.10 × 10-2 1.64†
(1.07-2.51)
2.21 × 10-2 1.88
(1.47-2.40)
4.99 × 10-7 0 0.74
1q23 RPL31P11 rs114384494 T 0.04 2.01†
(1.43-2.84)
7.04 × 10-5 2.18†
(1.08-4.38)
2.92 × 10-2 1.61†
(1.03-2.51)
3.62 × 10-2 1.89
(1.47-2.44)
8.86 × 10-7 0 0.67
1q23 ATF6 rs924777 G 0.12 1.23†
(1.03-1.46)
2.20 × 10-2 1.21
(0.89-1.64)
2.19 × 10-1 1.69
(1.36-2.10)
2.30 × 10-6 1.36
(1.20-1.54)
1.33 × 10-6 65 0.06
1q23 ATF6 rs2298019 A 0.12 1.23†
(1.03-1.47)
1.98 × 10-2 1.25†
(0.93-1.70)
1.43 × 10-1 1.66†
(1.33-2.06)
6.41 × 10-6 1.36
(1.20-1.54)
1.36 × 10-6 56 0.10
Definition of abbreviations: CI confidence interval, FRQ risk allele frequency, NHW non-Hispanic white, OR odds ratio, SNP single nucleotide polymorphism.
*Adjusted for age, sex, pack-years of cigarette smoking and genetic ancestry as summarized in the principal components.
†Imputed genotypes.
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analysis of CB vs. no CB within COPD subjects. The
novel SNPs on 11p15.5 were nominally significant (P <
0.01), whereas SNPs near FAM13A were not significant
(P > 0.1) (Additional file 1: Table S6).
Clinical and radiological characteristics were compared
according to genotypes of rs34391416 among all COPD-
Gene NHW subjects (Additional file 1: Table S7). There
were significant differences in parameters related to air-
way disease, including airway wall area% on inspiratory
chest CT scans and gas trapping on expiratory CT.
There were no differences in emphysema severity or dis-
tribution related to this SNP.
Since the meta-analysis of CB COPD relative to smok-
ing controls showed FAM13A as the top gene, we per-
formed additional analyses to ascertain whether SNPs
near FAM13A had different levels of statistical significance
between COPD with CB and COPD without CB. A meta-Figure 5 Local association plots for the top two loci in the meta-anal
subjects without chronic bronchitis in COPDGene non-Hispanic white
1q23. The x-axis is chromosomal position, and the y-axis shows the –log10
with other SNPs colored by degree of linkage disequilibrium (r2). Plots weranalysis of GWASs for COPD subjects without CB relative
to smoking controls (Figure 1) also showed FAM13A as
the top gene, which was followed by HHIP and IREB2
(Additional file 1: Table S8 and Additional file 1: Figure
S2). ORs and P values of previously known COPD risk al-
leles among our results from meta-analyses for CB COPD
or COPD without CB are summarized in Table 5. Permu-
tation testing revealed that differences of ORs between
our two meta-analyses were statistically significant at four
SNPs in FAM13A.
Discussion
Our GWAS meta-analysis of three studies of COPD sub-
jects with CB relative to smoking controls not only
reconfirmed previously known genome-wide significant
SNPs in FAM13A related to lung function [32,33] and
COPD [21-23], but also revealed a novel locus on
11p15.5, including EFCAB4A, CHID1, and AP2A2.ysis of COPD subjects with chronic bronchitis versus COPD
s, GenKOLS, and ECLIPSE. A. rs114931935 on 1q23. B. rs924777 on
P value. The most significant SNP at each gene is labeled in purple,
e created using LocusZoom.
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http://respiratory-research.com/content/15/1/113Proteins encoded by one or more of these three genes
could be involved in CB. Interestingly, this new region is
located next to MUC6 and MUC2 (Figure 5) [34]. Thus,
it is also possible that this genomic region influences
regulation of mucin genes to alter susceptibility to CB.
EFCAB4A encodes a protein involved in store-operated
Ca2+ entry. Intracellular Ca2+ was reported to regulate
MUC2 expression [34,35] and mucin secretion from airway
goblet cells [36]. In addition, a study demonstrated in-
creased intracellular Ca2+ levels in lymphocytes of COPD
patients, which correlated positively with the spirometric
grade of COPD [37]. Gene expression microarray analysis
of human bronchial epithelial cells identified overexpres-
sion of EFCAB4A during mucociliary differentiation [38].
While quantitative RT-PCR revealed high expression of
EFCAB4A in lung [39], a role for EFCAB4A in CB remains
to be defined.
Even though SNPs near CHID1 in the meta-analysis of
three GWASs did not show genome-wide significance,
rs147862429 was the most genome-wide significant in a
GWAS of COPDGene NHWs, with a P value of 2.90 ×
10-10. CHID1 encodes a saccharide- and LPS-binding pro-
tein, also called stabilin-1 interacting chitinase-like protein
(S1-CLP), with possible roles in pathogen sensing and
endotoxin neutralization [40]. It is expressed in cells of
monocytic, T lymphocyte, B lymphocyte, and epithelial
origin, and it is up-regulated by the Th2 cytokine
interleukin-4 and dexamethasone in macrophages [41].Table 5 Meta-analysis results of COPD with chronic bronchitis
smoking controls for COPD risk alleles previously demonstrat
smoking controls
Locus Gene SNP Risk
allele




FRQ OR P FRQ
4q22 FAM13A rs2869967* C 0.41 1.38 5.61 × 10-10 0.41
4q22 FAM13A rs4416442† C 0.40 1.38 6.87 × 10-10 0.41
4q22 FAM13A rs7671167‡ T 0.50 1.35 5.58 × 10-9 0.50
4q22 FAM13A rs1964516‡ T 0.50 1.35 1.04 × 10-8 0.50
4q31 HHIP-AS1 rs13141641† T 0.58 1.27 2.81 × 10-6 0.59
4q31 HHIP-AS1 rs13118928‡ A 0.58 1.24 2.72 × 10-5 0.59
15q25 CHRNA3 rs12914385† T 0.42 1.27 2.83 × 10-6 0.42
15q25 AGPHD1 rs8034191§ C 0.37 1.27 4.29 × 10-6 0.37
15q25 IREB2 rs11858836‡ A 0.35 1.25 4.10 × 10-5 0.36
19q13 RAB4B rs2604894‡ G 0.56 1.19 9.89 × 10-4 0.57
14q32 RIN3 rs754388† C 0.81 1.22 3.74 × 10-3 0.82
14q32 RIN3 rs17184313† C 0.82 1.20 6.85 × 10-3 0.83
Definition of abbreviations: FRQ risk allele frequency; OR odds ratio; SNP single nucl
*Cho MH, et al. Variants in FAM13A Are Associated With Chronic Obstructive Pulmo
†Cho MH, et al. unpublished data.
‡Cho MH, et al. A Genome-Wide Association Study of COPD Identifies a Susceptibili
§Pillai SG, et al. A Genome-Wide Association Study in Chronic Obstructive Pulmonar
PLoS Genet 2009;5:e1000421.Other human chitinase and chitinase-like proteins were
previously suggested to play a role in the development of
COPD [42]. Chitotriosidase (CHIT1) levels were elevated
in the bronchoalveolar lavage fluid of smokers with COPD
[43]. A chitinase-like protein, commonly known as YKL-
40, was also increased in the lungs of COPD patients [44].
A recent study demonstrated genetic associations between
chitinase gene variants and lung function level and rate of
decline in COPD patients from the Lung Health Study
[45]. Therefore, CHID1 may be involved in the pathogen-
esis of CB.
AP2A2 encodes adaptor protein complex 2 subunit
alpha-2, which has been shown to participate in the
endocytosis of clathrin-coated vesicles in interacting
with epsin-1 [46] and receptor endocytosis with SHC-
transforming protein 1 [47]. One study demonstrated
long-range interactions between the MUC2 promoter
and the adjacent AP2A2 gene by using quantitative
chromosome conformation capture (q3C) [48]. Al-
though human respiratory tract mucus contains mainly
MUC5AC and MUC5B along with smaller amounts of
MUC2, the distribution of MUC2 variable number tan-
dem repeat (VNTR) alleles was reported to be different
between asthmatics and non-asthmatics [49]. A follow-
up study demonstrated relatively strong LD between
SNPs in MUC2 and MUC5AC [50]. Therefore, AP2A2,
either alone or through interactions with MUC2, may
have a potential role in CB pathogenesis.(CB) vs. smoking controls and COPD without CB vs.
ed in genome-wide association studies of COPD vs.
D without CB vs.
king controls
Permutation testing to assess difference of OR
between two meta-analyses, 10,000 times
OR P P
1.29 9.73 × 10-10 1.10 × 10-3
1.29 6.97 × 10-10 2.30 × 10-3
1.25 6.63 × 10-8 3.00 × 10-4
1.24 1.12 × 10-7 8.00 × 10-4
1.25 2.18 × 10-8 1.77 × 10-1
1.25 3.15 × 10-8 4.54 × 10-1
1.22 7.86 × 10-7 5.75 × 10-2
1.22 1.34 × 10-6 5.13 × 10-2
1.23 9.27 × 10-7 4.19 × 10-1
1.16 4.70 × 10-4 1.28 × 10-1
1.29 2.37 × 10-6 5.84 × 10-2
1.28 4.36 × 10-6 1.92 × 10-2
eotide polymorphism.
nary Disease. Nat Genet 2010;42:200-202.
ty Locus on Chromosome 19q13. Hum Mol Genet 2012;21:947-957.
y Disease (COPD): Identification of Two Major Susceptibility Loci.
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http://respiratory-research.com/content/15/1/113In the primary meta-analysis of CB COPD relative to
smoking controls, we found the strongest signal within
FAM13A rather than the other known COPD suscepti-
bility genes, and permutation testing confirmed that
ORs of FAM13A SNPs were significantly higher than
those for non-CB COPD. While COPD is a complex
disease with marked phenotypic heterogeneity, most
previous genetic studies have dealt with COPD sub-
jects as one homogeneous group [20-22]. The current
study suggests that previously identified COPD risk al-
leles might have different effects on the development
of different COPD subtypes.
Although our secondary meta-analysis of CB COPD
relative to COPD without CB within the COPD popula-
tion failed to demonstrate genome-wide significant SNPs,
the fourth most significant SNP, rs2298019, was previously
identified as an expression quantitative trait locus (eQTL)
for ATF6 in lung tissue [51], with the risk allele associated
with decreased expression. ATF6 plays a major role in
transcriptional repression of endogenous cystic fibrosis
transmembrane conductance regulator (CFTR) under
endoplasmic reticulum stress [52] and is thought to be a
potential therapeutic target for cystic fibrosis (CF) [53]. In
addition to CF, suppressed CFTR function has been re-
ported in cigarette smokers and COPD patients without
CF [54,55]. Recently, roflumilast, approved to reduce
COPD exacerbations in COPD patients with CB, has been
reported to activate CFTR [56]. Since ATF6 is closely con-
nected with CFTR, genetic variants of ATF6 may play a
role in the pathogenesis of CB.
We found that SNPs in another gene (CYS1) on 2p25.1
demonstrated suggestive associations for CB. CYS1 is
enriched in the ciliary axoneme, and high expression in the
kidney and weak expression in the lung were reported [57].
While the top SNP, rs12692398 of CYS1, reached the
genome-wide significance threshold in both a GWAS of
only COPDGene NHWs and a meta-analysis of COPDGene
NHWs and GenKOLS, it lost significance in the meta-
analysis of all three cohorts (P = 1.66 × 10-4). It is unclear
why the association evidence for CB of this genomic region
within ECLIPSE was negative. In the meta-analysis of three
cohorts, the other two SNPs of CYS1, rs13000481 and
rs4574084 showed P values of 1.74 × 10-5 and 2.61× 10-5,
respectively, and LD between these two SNPs is high (0.94).
Our study has several limitations. First, we have not
identified the functional genetic variants within our asso-
ciation regions. Nevertheless, we found significant differ-
ences in radiological parameters related to airway wall
thickness according to genotypes of the novel top SNP,
rs34391416, within COPDGene. These CT parameters
have been frequently used as objective indicators of airway
disease [6,58]. Interestingly, there were no differences in
emphysema severity or distribution according to this SNP
genotype. Further studies will be required to identify thefunctional genetic variants within this region and to deter-
mine which gene that they influence. Second, we have not
performed any independent replication, although this ana-
lysis was a meta-analysis of three GWASs. However, a
supplemental meta-analysis of four cohorts by adding
COPDGene AAs also showed similar results as those of
three cohorts. Third, CB was present in some of our
smoking controls. However, an additional meta-analysis of
three GWASs of CB COPD versus smoking controls with-
out CB showed similar results.
Conclusions
We have identified a novel locus on 11p15.5, which in-
cludes several biologically plausible candidates (EFCAB4A,
CHID1 and AP2A2) as potential CB susceptibility genes.
We have also found significantly increased effect sizes of
FAM13A SNPs in COPD subjects with CB compared to
those without CB. Although our secondary GWAS of CB
versus no CB within COPD subjects did not show genome-
wide significant SNPs, a locus including ATF6 should be ex-
plored for its related functional consequences. This study
supports the concept that different genetic susceptibility
contributes to phenotypic heterogeneity within COPD.
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Table S1. Top results of the meta-analysis for COPD subjects with chronic
bronchitis (CB) versus COPD subjects without CB in COPDGene non-Hispanic
white and GenKOLS cohorts. Table S2. Baseline characteristics of COPD
subjects with CB and smokers with normal spirometry as a control group in
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Assessment of top results from COPD with CB versus smokers with
normal spirometry within the meta-analysis for COPD subjects with CB
versus without CB. Table S7. Clinical and radiological characteristics
according to genotypes of rs34391416 among subjects with COPD
and smoking controls among non-Hispanic whites of COPDGene.
Table S8. Top results of three Caucasian cohorts meta-analyses for
COPD subjects without CB versus smokers with normal spirometry.
Figure S1. Local association plots for significant loci for the meta-analysis
of COPD subjects with CB versus COPD subjects without CB in COPDGene
non-Hispanic whites and GenKOLS. The x-axis is chromosomal position,
and the y-axis shows the –log10 P value. The most significant SNP at each
locus is labeled in purple, with other SNPs colored by degree of linkage
disequilibrium (r2). Plots created using LocusZoom. Figure S2. (A)
The quantile–quantile plot and (B) Manhattan plot of –log10 P values
for the three-cohort meta-analysis including 1000 Genomes project
imputed data for (A) COPD subjects without CB versus smoking
controls after adjustment for age, sex, pack-years of cigarette smoking
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